Trials / Completed
CompletedNCT05467514
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- David Sanchez Garcia · Other Government
- Sex
- All
- Age
- 15 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the trail is investigate the effect of liraglutide 1.8mg as add-on to insulin for 6 months on carotid intima media thickness and cardiovascular risk factors in subjects with type 1 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide | Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
- First posted
- 2022-07-20
- Last updated
- 2023-03-02
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT05467514. Inclusion in this directory is not an endorsement.